+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry

Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry

Rheumatology 55(2): 286-290

To examine in detail the outcomes of biologic DMARD (bDMARD) discontinuation while in remission occurring in daily clinical practice settings. We examined a multicentre longitudinal registry of RA patients. We utilized data from the NinJa multicenter registry in Japan. Patients who used bDMARDs and had one or more successive visits in remission (defined by the clinical disease activity index (CDAI) ≤2.8) before discontinuation were included. The outcome of failing bDMARD-free disease control was defined as a composite of the following: re-use of bDMARDs, intensification of non-biologic DMARDs or of oral glucocorticoids, or loss of CDAI remission. Among 1037 patients who initially achieved remission on bDMARDs, 46 patients discontinued bDMARDs while remaining in remission. Of these 46 subjects, 41 (89.1%) were female, the median disease duration was 6.0 years and 31 (70.5%) had reported radiographical erosions. At the baseline, 27 (58.7%) used MTX and 19 (41.3%) used oral glucocorticoids. The bDMARD-free remission failure rate was estimated to be 67.4% at 1 year and 78.3% at 2 years. Loss of remission and reuse of bDMARDs were the more common reasons for failure. Lower CDAI within the remission range was associated with fewer failures. We found a high rate of failing bDMARD-free CDAI remission, indicating difficulty of maintaining disease control, even in patients who were in remission. Modification of non-biologic treatment was observed in some of the patients who remained in remission. Considering the cost of bDMARDs, such strategies for maintaining disease control after bDMARD discontinuation may be an important option.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 058242399

Download citation: RISBibTeXText

PMID: 26350484

DOI: 10.1093/rheumatology/kev329

Related references

Treatment discontinuation in patients with very early rheumatoid arthritis in sustained simplified disease activity index remission after synthetic disease-modifying anti-rheumatic drug administration. Modern Rheumatology 22(3): 346-352, 2012

A comparison of discontinuation rates of tofacitinib and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and Bayesian network meta-analysis. Clinical and Experimental Rheumatology 35(4): 689-699, 2017

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. Rheumatology 55(8): 1466-1476, 2016

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology 54(4): 683-691, 2015

New biologic and non biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Nihon Rinsho Men'eki Gakkai Kaishi 32(3): 149-159, 2009

Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort. Scandinavian Journal of Rheumatology 46(6): 425-431, 2017

AB1368Insights from a routine care rheumatoid arthritis registry in turkey (TRAV): A third of rheumatoid arthritis patients are in remission/low disease activity and 1/5 are on biologic agents. Annals of the Rheumatic Diseases 71(Suppl 3): 716.3-716, 2013

Sat0215Ultrasound Disease Activity at 3 Months Predicts the Clinical Response at 6 Months of Patients with Rheumatoid Arthritis Treated by Biologic Disease Modifying Anti-Rheumatic Drugs. Annals of the Rheumatic Diseases 73(Suppl 2): 667.3-668, 2014

FRI0179Comparative Effectiveness of Biologic Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis: Table 1. Annals of the Rheumatic Diseases 73(Suppl 2): 446.3-447, 2014

AB0312Predictors of Disease Course after The Discontinuation of Biologic Therapy in Rheumatoid Arthritis Patients with Long-Term Remission. Annals of the Rheumatic Diseases 75(Suppl 2): 1007.1-1007, 2016

THU0072A Novel Dose Reduction Therapy Using Biological Disease-Modifying Anti-Rheumatic Drugs To Target Matrix Metalloproteinase 3 Normalization Together with A Simplified Disease Activity Index 3.3 Yields Effects Non-Inferior To Standard Care in Rheumatoid Arthritis with Regards Maintaining Remission. Annals of the Rheumatic Diseases 75(Suppl 2): 204.3-205, 2016

Ultrasound disease activity of bilateral wrist and finger joints at three months reflects the clinical response at six months of patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs. Modern Rheumatology 27(2): 252-256, 2017

Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort. Clinical Rheumatology 33(8): 1061-1066, 2014

Rheumatoid arthritis pharmacotherapy and predictors of disease-modifying anti-rheumatic drug initiation in the early years of biologic use in Quebec, Canada. Rheumatology International: -, 2013

Low proportion of remission with aggressive initial disease modifying anti rheumatic drug (DMARD) therapy in patients with early inflammatory arthritis (EIA) using DAS, SDAI and CDAI remission criteria. 2006